PMID- 36090326
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220913
IS  - 2296-875X (Print)
IS  - 2296-875X (Electronic)
IS  - 2296-875X (Linking)
VI  - 9
DP  - 2022
TI  - Exploration of the Tumor Immune Landscape and Identification of Two Novel 
      Immunotherapy-Related Genes for Epstein-Barr virus-associated Gastric Carcinoma 
      via Integrated Bioinformatics Analysis.
PG  - 898733
LID - 10.3389/fsurg.2022.898733 [doi]
LID - 898733
AB  - Epstein-Barr virus (EBV)-associated gastric carcinoma (EBVaGC) is a specific 
      molecular subtype of gastric carcinoma with a high proportion of 
      tumor-infiltrating lymphocytes. It is a highly immunogenic tumor that may benefit 
      from immunotherapy. Hence, it is imperative to analyze the immune landscape and 
      identify immunotherapy biomarkers for EBVaGC. In our study, we investigated the 
      immune landscape and identified 10 hub genes for EBVaGC via integrated 
      bioinformatics analysis. We found that EBVaGC expressed more immune-related 
      genes, including common immune checkpoints and human leukocyte antigen (HLA) 
      genes than EBV-negative gastric carcinoma (EBVnGC). The immune score in EBVaGC 
      was higher, which means EBVaGC has greater immune cell infiltration. Ten hub 
      genes (CD4, STAT1, FCGR3A, IL10, C1QA, CXCL9, CXCL10, CXCR6, PD-L1, and CCL18) 
      were detected as candidate biomarkers for EBVaGC. Two hub genes, CXCL9 and CXCR6, 
      were identified as novel immunotherapy-related genes. Taken together, the results 
      of our comprehensive analysis of the immune microenvironment of EBVaGC revealed 
      its unique immune landscape, demonstrating that it is a highly immunogenic tumor. 
      Moreover, we identified hub genes that may serve as potential immunotherapy 
      biomarkers for EBVaGC.
CI  - Copyright (c) 2022 Deng, Wang, Zhao, Bai and Zhang.
FAU - Deng, Shi-Zhou
AU  - Deng SZ
AD  - Department of Clinical Oncology, Xijing Hospital, Air Force Medical University, 
      Xi'an, China.
FAU - Wang, Xiang-Xu
AU  - Wang XX
AD  - Department of Clinical Oncology, Xijing Hospital, Air Force Medical University, 
      Xi'an, China.
FAU - Zhao, Xing-Yu
AU  - Zhao XY
AD  - State Key Laboratory of Cancer Biology, Xijing Hospital of Digestive Diseases, 
      Air Force Medical University, Xi'an, China.
FAU - Bai, Yin-Miao
AU  - Bai YM
AD  - Department of Clinical Oncology, Xijing Hospital, Air Force Medical University, 
      Xi'an, China.
FAU - Zhang, Hong-Mei
AU  - Zhang HM
AD  - Department of Clinical Oncology, Xijing Hospital, Air Force Medical University, 
      Xi'an, China.
LA  - eng
PT  - Journal Article
DEP - 20220523
PL  - Switzerland
TA  - Front Surg
JT  - Frontiers in surgery
JID - 101645127
PMC - PMC9450882
OTO - NOTNLM
OT  - EBVaGC
OT  - bioinformatics analysis
OT  - biomarker
OT  - gastric carcinoma
OT  - tumor microenvironment
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/09/13 06:00
MHDA- 2022/09/13 06:01
PMCR- 2022/05/23
CRDT- 2022/09/12 03:41
PHST- 2022/03/17 00:00 [received]
PHST- 2022/04/27 00:00 [accepted]
PHST- 2022/09/12 03:41 [entrez]
PHST- 2022/09/13 06:00 [pubmed]
PHST- 2022/09/13 06:01 [medline]
PHST- 2022/05/23 00:00 [pmc-release]
AID - 10.3389/fsurg.2022.898733 [doi]
PST - epublish
SO  - Front Surg. 2022 May 23;9:898733. doi: 10.3389/fsurg.2022.898733. eCollection 
      2022.